Medical/Pharmaceuticals

MINDCURE Announces Inclusion in AdvisorShares Psychedelics ETF

MINDCURE Announces Inclusion in AdvisorShares Psychedelics ETF

PSIL offers exposure to biotechnology, pharmaceutical and life sciences companies that are leading the emerging psychedelics medicine industry. The ETF is actively managed and concentrates its investments in companies receiving the majority of their net revenue or allocating the majority of their assets from psychedelic drugs.

Kelsey Ramsden, MINDCURE President and CEO, said: “MINDCURE’s inclusion in the AdvisorShares Psychedelics ETF is further validation of our strategy of integrating digital therapeutics with psychedelic medicine to improve mental health and increase productivity. MINDCURE is proud to be acknowledged as a leader in this emerging space and our inclusion in the ETF will increase investor awareness to the Company and the benefits of psychedelic treatment methods to improve mental health.”

For more information visit Manlitics B2BTechresearchsGlobalmartek

Previous ArticleNext Article